AVITA Medical Presents New Clinical Data at ABA Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy RCEL?
Source: Newsfilter
- Clinical Data Presentation: AVITA Medical showcased new clinical study data on Cohealyx at the 2026 American Burn Association Annual Meeting, emphasizing its significance in wound healing, which is expected to enhance patient recovery speed and optimize resource utilization.
- Multi-Center Study Progress: Interim analysis from the Cohealyx-I multi-center study indicates that using this product can significantly reduce time to skin grafting, reinforcing its clinical benchmarks in complex wound management and potentially driving market acceptance.
- Comprehensive Wound Management: Through 19 presentations featuring RECELL, Cohealyx, and PermeaDerm, AVITA Medical highlighted its holistic approach to wound management aimed at improving patient outcomes and reducing hospital stays, which holds substantial competitive market significance.
- New Booth Experience: At the meeting, AVITA Medical launched a new booth experience themed “Healing at the Speed of Life,” showcasing its innovative vision in burn and acute wound care, which may attract greater attention from healthcare professionals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCEL
Wall Street analysts forecast RCEL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 5.000
Low
3.00
Averages
4.25
High
5.50
Current: 5.000
Low
3.00
Averages
4.25
High
5.50
About RCEL
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AVITA Founder Receives Lifetime Achievement Award
- Lifetime Achievement Award: Professor Fiona Wood, founder of AVITA Medical, has been awarded the Lifetime Achievement Award by the American Burn Association, recognizing her outstanding contributions to burn care, research, and education, highlighting her profound impact on modern burn care.
- Innovative Technology: The RECELL® Spray-On Skin technology developed by Professor Wood significantly enhances the healing process for burn patients by reducing donor skin requirements and improving clinical outcomes, driving advancements in global burn care.
- Industry Leadership: With over three decades of leadership in burn care, Professor Wood serves as the Director of the Burns Service of Western Australia, influencing clinical practices worldwide and laying the groundwork for future burn treatments.
- Global Recognition: Professor Wood's achievements have gained international recognition, including the Officer of the Order of Australia and Australian of the Year in 2005, with her research reflected in hundreds of scientific publications, further advancing burn care globally.
See More
AVITA Medical's Cohealyx Accelerates Skin Grafting Time
- Product Performance Improvement: AVITA Medical's Cohealyx product demonstrates remarkable efficacy in wound care, reducing skin grafting time from a benchmark of 33.2 days to 13.6 days, indicating a significant clinical advantage that could redefine wound preparation standards.
- Clinical Trial Results: The Cohealyx-I multi-center study analysis of 40 patients shows a median grafting time of 11 days, with 75% of grafts occurring within 14 days, further validating the product's effectiveness and rapid response capabilities.
- Market Potential: The release of this data led to a ~15% increase in AVITA Medical's stock price on Tuesday, reflecting market optimism regarding the product's prospects and potentially driving the company's market share growth in wound care.
- Future Outlook: AVITA's interim CEO Cary Vance noted that this data strengthens their belief that Cohealyx can set a new benchmark in wound bed preparation, with full clinical data expected to be released this year to further support product marketing.
See More
AVITA Medical Secures Up to $25.5M Deal with BARDA for RECELL Supply
- Significant Agreement Value: AVITA Medical's deal with the Biomedical Advanced Research and Development Authority (BARDA) is valued at up to $25.5 million, aimed at enhancing U.S. readiness for mass burn casualty incidents, highlighting the company's importance and potential in the medical field.
- Product Delivery Plan: Under the 10-year agreement, BARDA will accept delivery of 3,000 units of RECELL, allowing AVITA to promote its leading product across the U.S., thereby enhancing the company's influence in the wound care market.
- Clear Revenue Expectations: AVITA anticipates recognizing $3.97 million in revenue over the next decade, primarily from annual access-maintenance fees and readiness support, which provides financial stability and lays a foundation for future growth.
- Optimistic Market Outlook: AVITA Medical has set a revenue target of $80 million to $85 million for 2026, with reimbursement clarity expected to drive multi-product utilization, further strengthening the company's market competitiveness and profitability.
See More
AVITA MEDICAL: PROJECT PARTIALLY OR FULLY FINANCED BY FEDERAL FUNDING FROM THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Project Overview: The Avita Medical project is funded in whole or in part by federal funds from the U.S. Department of Health and Human Services.
- Funding Source: The project receives financial support from federal resources aimed at enhancing health and human services.
See More
AVITA MEDICAL INC ENTERS INTO $25.5 MILLION AGREEMENT FOR PROJECT BIOSHIELD
- Agreement Overview: Avita Medical has entered into a significant agreement valued at up to $25.5 million under Project BioShield.
- Funding Purpose: The funding is aimed at advancing the development of medical countermeasures for public health emergencies.
See More
AVITA MEDICAL ENTERS INTO A 10-YEAR BARDA CONTRACT VALUED AT UP TO $25.5M TO ENHANCE U.S. BURN EMERGENCY READINESS
Agreement Overview: Avita Medical has entered a 10-year agreement worth up to $25.5 million with U.S. Burn Emergency Preparedness.
Focus on Preparedness: The partnership aims to enhance emergency preparedness for burn treatment and care.
See More
AVITA Founder Receives Lifetime Achievement Award
- Lifetime Achievement Award: Professor Fiona Wood, founder of AVITA Medical, has been awarded the Lifetime Achievement Award by the American Burn Association, recognizing her outstanding contributions to burn care, research, and education, highlighting her profound impact on modern burn care.
- Innovative Technology: The RECELL® Spray-On Skin technology developed by Professor Wood significantly enhances the healing process for burn patients by reducing donor skin requirements and improving clinical outcomes, driving advancements in global burn care.
- Industry Leadership: With over three decades of leadership in burn care, Professor Wood serves as the Director of the Burns Service of Western Australia, influencing clinical practices worldwide and laying the groundwork for future burn treatments.
- Global Recognition: Professor Wood's achievements have gained international recognition, including the Officer of the Order of Australia and Australian of the Year in 2005, with her research reflected in hundreds of scientific publications, further advancing burn care globally.
See More
AVITA Medical's Cohealyx Accelerates Skin Grafting Time
- Product Performance Improvement: AVITA Medical's Cohealyx product demonstrates remarkable efficacy in wound care, reducing skin grafting time from a benchmark of 33.2 days to 13.6 days, indicating a significant clinical advantage that could redefine wound preparation standards.
- Clinical Trial Results: The Cohealyx-I multi-center study analysis of 40 patients shows a median grafting time of 11 days, with 75% of grafts occurring within 14 days, further validating the product's effectiveness and rapid response capabilities.
- Market Potential: The release of this data led to a ~15% increase in AVITA Medical's stock price on Tuesday, reflecting market optimism regarding the product's prospects and potentially driving the company's market share growth in wound care.
- Future Outlook: AVITA's interim CEO Cary Vance noted that this data strengthens their belief that Cohealyx can set a new benchmark in wound bed preparation, with full clinical data expected to be released this year to further support product marketing.
See More
AVITA Medical Secures Up to $25.5M Deal with BARDA for RECELL Supply
- Significant Agreement Value: AVITA Medical's deal with the Biomedical Advanced Research and Development Authority (BARDA) is valued at up to $25.5 million, aimed at enhancing U.S. readiness for mass burn casualty incidents, highlighting the company's importance and potential in the medical field.
- Product Delivery Plan: Under the 10-year agreement, BARDA will accept delivery of 3,000 units of RECELL, allowing AVITA to promote its leading product across the U.S., thereby enhancing the company's influence in the wound care market.
- Clear Revenue Expectations: AVITA anticipates recognizing $3.97 million in revenue over the next decade, primarily from annual access-maintenance fees and readiness support, which provides financial stability and lays a foundation for future growth.
- Optimistic Market Outlook: AVITA Medical has set a revenue target of $80 million to $85 million for 2026, with reimbursement clarity expected to drive multi-product utilization, further strengthening the company's market competitiveness and profitability.
See More
AVITA MEDICAL: PROJECT PARTIALLY OR FULLY FINANCED BY FEDERAL FUNDING FROM THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Project Overview: The Avita Medical project is funded in whole or in part by federal funds from the U.S. Department of Health and Human Services.
- Funding Source: The project receives financial support from federal resources aimed at enhancing health and human services.
See More
AVITA MEDICAL INC ENTERS INTO $25.5 MILLION AGREEMENT FOR PROJECT BIOSHIELD
- Agreement Overview: Avita Medical has entered into a significant agreement valued at up to $25.5 million under Project BioShield.
- Funding Purpose: The funding is aimed at advancing the development of medical countermeasures for public health emergencies.
See More
AVITA MEDICAL ENTERS INTO A 10-YEAR BARDA CONTRACT VALUED AT UP TO $25.5M TO ENHANCE U.S. BURN EMERGENCY READINESS
Agreement Overview: Avita Medical has entered a 10-year agreement worth up to $25.5 million with U.S. Burn Emergency Preparedness.
Focus on Preparedness: The partnership aims to enhance emergency preparedness for burn treatment and care.
See More
